ABBSTRACTGrowth or survival of Listeria monocytogenes in cold‐smoked salmon; sliced, cooked ham; sliced, roasted turkey; shrimp salad; and coleslaw obtained at retail supermarkets stored at 5 °C, 7 °C, or 10 °C (41 °F, 45 °F, or 50 °F, respectively) for up to 14 d was evaluated. Cold‐smoked salmon, ham, and turkey were obtained in case‐ready, vacuum packages. All food products were stored aerobically to reflect additional handling within the retail supermarket. Cold‐smoked salmon, ham, and turkey supported the growth of L. monocytogenes at all 3 storage temperatures. Fitted growth curves of initial populations (about 3 log10 colony‐forming units [CFU]/g) in cold‐smoked salmon, ham, and turkey stored at 5 °C achieved maximal growth rates of 0.29, 0.45, and 0.42 log10 CFU/g growth per day, respectively. Storage at 10 °C increased the estimated maximal growth rate of the pathogen by 0.56 to 1.08 log10 CFU/ g growth per day compared with storage at 5 °C. A decline in populations of L. monocytogenes was observed in shrimp salad and coleslaw, and the rate of decline was influenced by storage temperature. Retention of viability was higher in shrimp salad than in coleslaw, where populations fell 1.2, 1.8, and 2.5 log10 CFU/g at 5 °C, 7 °C, and 10 °C, respectively, after 14 d of storage. Inability of shrimp salad and coleslaw to support the growth of L. monocytogenes may be attributed to the acidic pH (4.8 and 4.5, respectively) of the formulations used in this study. Results show that the behavior of L. monocytogenes in potentially hazardous ready‐to‐eat foods is dependent upon the composition of individual food products as well as storage temperature.

BackgroundReoperations occur frequently after initial lumpectomy for breast cancer. The authors hypothesized that the receipt of neoadjuvant chemotherapy (NAC) is associated with fewer reoperations.MethodsThe association between timing of chemotherapy and reoperation rates (ROR) after lumpectomy was investigated for patients with stages 1–3 breast cancer in the National Cancer Database (NCDB) from 2010 to 2013 by multivariable logistic regression modeling. Then propensity score-matching was performed.ResultsThe unadjusted ROR for 71,627 stages 1–3 patients was 11.4% for those who had NAC compared with 20.3% for those who had postoperative chemotherapy (p < 0.001) (odds ratio [OR] 0.53; 95% confidence interval [CI] 0.49–0.57; p < 0.001). The ORs for the reoperations performed for patients with stages 1, 2, and 3 cancers who received NAC were respectively 0.65 (95% CI 0.56–0.75), 0.50 (95% CI 0.45–0.56), and 0.27 (95% CI 0.19–0.38) The p values for all were lower than 0.001.ConclusionFor a population of patients receiving chemotherapy, the receipt of chemotherapy before instead of after surgery was associated with fewer reoperations after initial lumpectomy for breast cancer.

No abstract

The finding that NAC was associated with higher M&M in lumpectomy patients during 2011 to 2012 warrants further investigation. Therefore, we recommend that the NSQIP database reinstitute the NAC variable to allow monitoring during anticipated changes in chemotherapy agents and protocols.

The AOAC use-dilution test (UDT) for bactericidal disinfectant efficacy (Method 964.02) has often been criticized for its extreme variability in test results, particularly for quaternary ammonium compound (QAC)-based disinfectants against Pseudomonas aeruginosa. While efforts are under way to develop a new and better test method for hospital disinfectant products that is globally acceptable, U.S. manufacturers and formulators of QAC products must continue in the interim to measure their product performance against the current UDT method. Therefore, continued variability in the UDT places an unnecessary and unfair burden on U.S. QAC product manufacturers to ensure that their products perform against an, at best, unreliable test method. This article reports on evaluations that were conducted to attempt to identify key sources of UDT method variability and to find ways to mitigate their impact on test outcomes for the method. The results of testing across 4 laboratories, involving over 6015 carriers, determined that operator error was a key factor in test variability. This variability was found to be significantly minimized by the inclusion of a simple culture dilution step. The findings from this study suggest possible refinements to the current AOAC UDT method that would serve to improve the overall ruggedness and reliability of the method and to optimize recovery of cells from the carrier surface, thereby further improving the accuracy and reproducibility of counts and test outcomes until such time as a replacement method is implemented.